(4-苯氧基苯氧基)乙酸 | 38559-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-苯氧基苯氧基)乙酸
• 英文名称: 4-Carboxymethoxy-diphenylether
• 英文别名: p-Phenoxy-phenoxyessigsaeure；(4-phenoxy-phenoxy)-acetic acid；(4-Phenoxy-phenoxy)-essigsaeure；O-(4-Phenoxy-phenyl)-glykolsaeure；2-(4-Phenoxyphenoxy)acetic acid
• CAS: 38559-90-9
• 化学式: C₁₄H₁₂O₄
• mdl: MFCD02720439
• 分子量: 244.247
• InChiKey: NUTWPVOGVQFHTI-UHFFFAOYSA-N

物化性质

• 熔点：
  125 °C
• 沸点：
  401.6±25.0 °C(Predicted)
• 密度：
  1.251±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  (4-苯氧基苯氧基)乙酸 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 N-[(2,6-difluorophenylcarbamoyl)methyl]-2-(4-phenoxyphenoxy)acetamide
  参考文献：
  名称：

  In silico and pharmacological screenings identify novel serine racemase inhibitors

  摘要：

  D-Serine is a coagonist of the N-methyl-D-aspartate (NMDA)-type glutamate receptor and its biosynthesis is catalyzed by serine racemase (SR). The overactivation of the NMDA receptor has been implicated in the development of neurodegenerative diseases, strokes, and epileptic seizures, thus, the inhibitors of SR have potential against these pathological states. Here, we have developed novel inhibitors of SR by in silico screening and in vitro enzyme assay. The newly developed inhibitors have lower IC50 value comparing with that of malonate, one of the standard SR inhibitor. The structural features of novel inhibitors suggest the importance of central amide structure having a phenoxy substituent in their structure for the SR inhibitory activity. The present findings suggest the importance and rational development of new drugs for diseases of NMDAR overactivation.

  DOI：

  10.1016/j.bmcl.2014.07.003
• 作为产物：
  描述：

  4-苯氧基苯酚 在 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 (4-苯氧基苯氧基)乙酸
  参考文献：
  名称：

  In silico and pharmacological screenings identify novel serine racemase inhibitors

  摘要：

  D-Serine is a coagonist of the N-methyl-D-aspartate (NMDA)-type glutamate receptor and its biosynthesis is catalyzed by serine racemase (SR). The overactivation of the NMDA receptor has been implicated in the development of neurodegenerative diseases, strokes, and epileptic seizures, thus, the inhibitors of SR have potential against these pathological states. Here, we have developed novel inhibitors of SR by in silico screening and in vitro enzyme assay. The newly developed inhibitors have lower IC50 value comparing with that of malonate, one of the standard SR inhibitor. The structural features of novel inhibitors suggest the importance of central amide structure having a phenoxy substituent in their structure for the SR inhibitory activity. The present findings suggest the importance and rational development of new drugs for diseases of NMDAR overactivation.

  DOI：

  10.1016/j.bmcl.2014.07.003

文献信息

• Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors
  作者：Yajun Yang、Ke Wang、Bo Wu、Ying Yang、Fangfang Lai、Xiaoguang Chen、Zhiyan Xiao

  DOI：10.1016/j.bmcl.2020.127508

  日期：2020.11

  and synthesized based on the known proteasome inhibitor PI-1840. Most of them showed significant inhibition against the β5c subunit of human 20S proteasome, and five of them exhibited IC50 values at the sub-micromolar level, which were comparable to or even more potent than PI-1840. The most active two (1c and 1d) showed IC50 values of 0.12 and 0.18 μM against the β5c subunit, respectively, while they

  基于已知的蛋白酶体抑制剂PI-1840设计并合成了三十种新型三芳基化合物。它们中的大多数显示出对人20S蛋白酶体β5c亚基的显着抑制作用，并且其中五种在亚微摩尔水平显示出IC 50值，与PI-1840相当甚至更高。最活跃的两个（1c和1d）对β5c亚基的IC 50值分别为0.12和0.18μM，而对β2c，β1c和β5i亚基没有明显的抑制作用。分子对接为亚基选择性提供了有益的线索。本文鉴定的有效和亚基选择性蛋白酶体抑制剂代表了用于进一步分子优化的新化学模板。
• ACTIVATOR OF ADIPONECTIN RECEPTOR
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20160214967A1

  公开（公告）日：2016-07-28

  An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y 1 is (CHR 2 ) a — or the like, X is CH or N, R 1 is a C 1-7 alkyl group, m is an integer of 0-4, Y 2 is *—O—CH 2 —CONH—, *—CONH—(CH 2 ) b —CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

  提供了一种用于激活AdipoR1和AdipoR2的AdipoR激活剂。以下式（1）表示的化合物，其中A是取代或未取代的芳基或类似物，Y1是（CHR2）a—或类似物，X是CH或N，R1是C1-7烷基基团，m是0-4的整数，Y2是*—O—CH2—CONH—，*—CONH—（CH2）b—CO—或类似物，Z是环基团，B可以是Z代表的环基团的取代基，n是0-3的整数。
• Inhibitors of akt (protein kinase b)
  申请人：Al-Awar Salim Rima

  公开号：US20070043040A1

  公开（公告）日：2007-02-22

  The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.

  本发明涉及化合物式(I)：作为AKT活性抑制剂，可用于治疗易感性肿瘤和病毒感染。
• ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS
  申请人：Inoue Tadashi

  公开号：US20120101105A1

  公开（公告）日：2012-04-26

  The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na v1.3 and Na v1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

  本发明涉及公式(I)或其药学上可接受的盐的芳基取代羧酰胺衍生物，其具有T型钙通道或电压门控钠通道的阻滞活性，如Nav1.3和Nav1.7等Tetrodotoxin敏感(TTX-S)阻滞剂，并且在涉及T型钙通道或电压门控钠通道的疾病或疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及在涉及T型钙通道或电压门控钠通道的疾病或疾病的预防或治疗中使用这些化合物和组合物的用途。
• ADIPONECTIN RECEPTOR-ACTIVATING COMPOUND
  申请人：The University of Tokyo

  公开号：EP3053911A1

  公开（公告）日：2016-08-10

  An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y1 is (CHR2)a- or the like, X is CH or N, R1 is a C1-7 alkyl group, m is an integer of 0-4, Y2 is *-O-CH2-CONH-, *-CONH-(CH2)b-CO- or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

  本发明提供了一种可同时激活 AdipoR1 和 AdipoR2 的 AdipoR 激活剂。一种由下式（1）代表的化合物，其中 A 是取代或未取代的芳基或类似物，Y1 是 (CHR2)a- 或类似物，X 是 CH 或 N，R1 是 C1-7 烷基，m 是 0-4 的整数，Y2 是 *-O-CH2-CONH-、*-CONH-(CH2)b-CO- 或类似物，Z 是环状基团，B 可以是 Z 所代表的环状基团的取代基，n 是 0-3 的整数。